ArticleScience China. Life sciences2025
Unveiling the clinical significance of RNA pseudouridine in colorectal cancer.
Article in Science China. Life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pseudouridine synthase 7 as a context-specific therapeutic target in cancer.The Journal of pharmacology and experimental therapeutics · 2026Review
- Molecular Insights into Widespread Pseudouridine RNA Modifications: Implications for Women's Health and Disease.Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is a prevalent malignancy characterized by rising incidence and mortality rates worldwide. The involvement of RNA pseudouridine synthase enzymes in CRC development is well-documented, yet the transcriptomic profile of pseudouridine (Ψ) in CRC remains largely unexplored. This study explored the transcriptomic landscape of Ψ in CRC by analyzing 21 biopsies and their corresponding adjacent healthy tissues, along with blood samples from 10 patients using PRAISE, a quantitative pseudouridine sequencing technology at base resolution. Our findings revealed significant differences in Ψ distribution and levels between CRC samples and adjacent normal tissues, correlating with the expression levels of DKC1, PUS7L, and PUS10. Notably, distinct Ψ levels of snoRNAs could serve as potential tumor biomarkers. Furthermore, we assessed the clinical utility of Ψ in both tumor and blood samples. Differentiated Ψ levels showed promising correlations with clinical markers such as cancer antigen 125, cancer antigen 153, and cancer antigen 199 in tumors, whereas Ψ sites in blood revealed enhanced correlations with routine blood indicators like white blood cells (WBCs) and alpha-fetoprotein (AFP). These findings underscore the significant role of RNA Ψ in CRC, providing valuable insights into its potential applications for clinical diagnosis and treatment.
Indexed as
Identifiers
40189490What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.